Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy.

Shin HK, Jones PB, Garcia-Alloza M, Borrelli L, Greenberg SM, Bacskai BJ, Frosch MP, Hyman BT, Moskowitz MA, Ayata C.

Brain. 2007 Sep;130(Pt 9):2310-9.

2.
3.

Age-dependent neurovascular dysfunction and damage in a mouse model of cerebral amyloid angiopathy.

Park L, Koizumi K, El Jamal S, Zhou P, Previti ML, Van Nostrand WE, Carlson G, Iadecola C.

Stroke. 2014 Jun;45(6):1815-21. doi: 10.1161/STROKEAHA.114.005179.

4.

Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition.

Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, Cirrito JR, Milner E, Holtzman DM, Zipfel GJ.

J Neurosci. 2008 Dec 10;28(50):13542-50. doi: 10.1523/JNEUROSCI.4686-08.2008.

5.

Hypertension enhances Aβ-induced neurovascular dysfunction, promotes β-secretase activity, and leads to amyloidogenic processing of APP.

Faraco G, Park L, Zhou P, Luo W, Paul SM, Anrather J, Iadecola C.

J Cereb Blood Flow Metab. 2016 Jan;36(1):241-52.

6.

Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons.

Van Dorpe J, Smeijers L, Dewachter I, Nuyens D, Spittaels K, Van Den Haute C, Mercken M, Moechars D, Laenen I, Kuiperi C, Bruynseels K, Tesseur I, Loos R, Vanderstichele H, Checler F, Sciot R, Van Leuven F.

Am J Pathol. 2000 Oct;157(4):1283-98.

7.

Mechanisms of peripheral microvascular dysfunction in transgenic mice overexpressing the Alzheimer's disease amyloid Abeta protein.

Khalil Z, Poliviou H, Maynard CJ, Beyreuther K, Masters CL, Li QX.

J Alzheimers Dis. 2002 Dec;4(6):467-78.

PMID:
12515898
8.

Early-onset formation of parenchymal plaque amyloid abrogates cerebral microvascular amyloid accumulation in transgenic mice.

Xu F, Kotarba AE, Ou-Yang MH, Fu Z, Davis J, Smith SO, Van Nostrand WE.

J Biol Chem. 2014 Jun 20;289(25):17895-908. doi: 10.1074/jbc.M113.536565.

9.

Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice.

Petrushina I, Ghochikyan A, Mkrtichyan M, Mamikonyan G, Movsesyan N, Ajdari R, Vasilevko V, Karapetyan A, Lees A, Agadjanyan MG, Cribbs DH.

J Neuroinflammation. 2008 Sep 29;5:42. doi: 10.1186/1742-2094-5-42.

10.

Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow.

Li H, Guo Q, Inoue T, Polito VA, Tabuchi K, Hammer RE, Pautler RG, Taffet GE, Zheng H.

Mol Neurodegener. 2014 Aug 9;9:28. doi: 10.1186/1750-1326-9-28.

11.

Vascular response to acetazolamide decreases as a function of age in the arcA beta mouse model of cerebral amyloidosis.

Princz-Kranz FL, Mueggler T, Knobloch M, Nitsch RM, Rudin M.

Neurobiol Dis. 2010 Oct;40(1):284-92. doi: 10.1016/j.nbd.2010.06.002.

PMID:
20600914
12.

Long-term incubation with beta-amyloid peptides impairs endothelium-dependent vasodilatation in isolated rat basilar artery.

Chisari M, Merlo S, Sortino MA, Salomone S.

Pharmacol Res. 2010 Feb;61(2):157-61. doi: 10.1016/j.phrs.2009.09.004.

PMID:
19782136
13.

Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models.

Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, Sullivan PM, Holtzman DM.

Acta Neuropathol Commun. 2015 Nov 10;3:70. doi: 10.1186/s40478-015-0250-y.

14.

Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.

Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM.

J Neurosci. 2005 Mar 16;25(11):2803-10.

15.

Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity.

Bales KR, O'Neill SM, Pozdnyakov N, Pan F, Caouette D, Pi Y, Wood KM, Volfson D, Cirrito JR, Han BH, Johnson AW, Zipfel GJ, Samad TA.

Brain. 2016 Feb;139(Pt 2):563-77. doi: 10.1093/brain/awv313.

PMID:
26493635
16.

Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice.

Paris D, Quadros A, Humphrey J, Patel N, Crescentini R, Crawford F, Mullan M.

Brain Res. 2004 Feb 27;999(1):53-61.

PMID:
14746921
17.

Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease.

Bi Oh S, Suh N, Kim I, Lee JY.

Brain Res. 2015 Feb 9;1597:159-67. doi: 10.1016/j.brainres.2014.11.042.

PMID:
25454795
18.

Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation.

Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S, Ashe KH, Carlson GA, Iadecola C.

Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9735-40.

19.

Hereditary and sporadic forms of abeta-cerebrovascular amyloidosis and relevant transgenic mouse models.

Kumar-Singh S.

Int J Mol Sci. 2009 Apr 23;10(4):1872-95. doi: 10.3390/ijms10041872. Review.

Items per page

Supplemental Content

Support Center